Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
73 Views
Emedinexus 11 June 2025
The U.S. Food and Drug Administration (FDA) has granted approval for Yorvipath (palopegteriparatide) for subcutaneous use in adults with hypoparathyroidism. This treatment targets the insufficient production of parathyroid hormone, a condition that can lead to low calcium levels.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}